Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer's disease.

Gayathri Nair SekharAlice L FleckneySevda Tomova BoyanovaHuzefa RupawalaRachel LoHao WangDoaa B FaragKhondaker Miraz RahmanMartin BroadstockSuzanne ReevesSarah Ann Thomas

Published in: Fluids and barriers of the CNS (2019)

Together our research indicates that the increased sensitivity of individuals with Alzheimer's to amisulpride is related to previously unreported changes in function and expression of SLC transporters at the BBB (in particular PMAT and MATE1). Dose adjustments may be required for drugs that are substrates of these transporters when prescribing for individuals with AD.

Keyphrases

blood brain barrier
cognitive decline
cerebral ischemia
poor prognosis
primary care
emergency department
mild cognitive impairment
binding protein
subarachnoid hemorrhage
brain injury
drug induced